

Clinical implication of smoking among patients with schizophrenia at a Tertiary Institution in South East Nigeria

Chinyere Aguocha¹, Richard Uwakwe², Emmanuel Olose³, Kennedy Amadi⁴, Gabriel Onyeama⁴, Chukwuma Duru⁵

1. Imo state university Teaching Hospital, Orlu, imo state, Nigeria, Department of Medicine; Imo state university , owerri, imo state, Nigeria, Department of Medicine.
2. Nnamdi Azikiwe University Teaching Hospital, Mental Health.
3. Department of Psychiatry, University Of Calabar, Cross Rivers, Nigeria.
4. University of Nigeria, Department of Psychological Medicine
5. Imo State University Teaching Hospital, Orlu, Nigeria. , Community Medicine

Abstract:

Background: The chronic and debilitating nature of schizophrenia creates a disease with marked clinical and economic consequences. Smoking in schizophrenia appears to be associated with increased psychopathology and disability.

Objective: The aim of this study was to determine if cigarette smoking in schizophrenia is associated with increased disability and psychopathology.

Materials and methods: This was a cross-sectional descriptive study in which 367 out-patients with International Classification of Diseases (ICD) 10 diagnosis of schizophrenia were recruited. Socio-demographic questionnaire, Present State Examination (PSE) 10, Positive And Negative Syndrome Scale (PANSS) and World Health Organization Disability Assessment Schedule (WHODAS) were administered. Data was analyzed using a software package SPSS version 15.

Results: There was no significant difference in the mean PANSS scores of smokers and non-smokers. Current smoking was associated with increased disability ($F=5.39$, $p=0.02$). Total PANSS score significantly predicted disability ($F(3,71)=5.60$, $p=0.002$, $R^2=0.19$). There was no significant association between positive or negative symptoms and being a smoker or non-smoker.

Conclusion: The results of this study revealed that smoking in Nigerian schizophrenia patients is associated with significant disability. Measures should be put in place to discourage cigarette smoking among Nigerian patients with schizophrenia.

Keywords: Schizophrenia, smoking, psychopathology, disability, Nigeria.

DOI: <https://dx.doi.org/10.4314/ahs.v18i1.14>

Cite as: Aguocha C, Uwakwe R, Olose E, Amadi K, Onyeama G, Duru C. Clinical implication of smoking among patients with Schizophrenia at a Tertiary Institution in South East Nigeria. *Afri Health Sci* 2018;18(1): 102-110. <https://dx.doi.org/10.4314/ahs.v18i1.14>

Introduction

Schizophrenia has been ranked as one of the ten most debilitating diseases worldwide and accounts for 1.1% of

the total disability-adjusted life years and 2.8% of years lived with disability^{1,2}. Studies that compared disability across mental disorders showed that schizophrenia ranked ahead of dementia, depression, obsessive compulsive disorder, alcoholism and bipolar affective disorder^{3,4,5}. Schizophrenia leads to a breakdown in interpersonal and occupational achievement⁶. Psychopathology has been recognized as one of the most important factors in disability⁷. Disability in schizophrenia persists for years after symptom remission⁸. Disability affects social participation mainly and is associated with age of the patient and severity of psychotic symptoms⁹. Nicotine is by far the most prevalent drug abused by

Corresponding author:

Chinyere Aguocha,
imo state university teaching hospital,
Orlu, imo state, nigeria,
Dept of medicine; Imo state university ,
Owerri, imo state, Nigeria, dept of medicine.
Email: aguochainvest@yahoo.com,
aguochachinyere@yahoo.com

schizophrenia patients and it increases mortality rate and financial burden incurred in the course of treatment^{10,11,12,13}. The effect of smoking on the outcome of schizophrenia has been rather controversial^{10,13,14,15}.

Understanding the effects of smoking on disability and psychopathology in schizophrenia would help develop appropriate evidence based biological and psychosocial interventions for these patients. No studies investigating the influence of cigarette smoking on the clinical expression of schizophrenia as measured via Positive And Negative Syndrome Scale (PANSS) and disability via World Health Organization Disability Assessment Schedule (WHODAS) have been reported in the Nigerian South East population. This article therefore explored the hypothesis that smoking leads to increased psychopathology and disability among patients with schizophrenia in South East Nigeria.

Subjects and methods

This study was carried out at the Federal Neuropsychiatric Hospital located at Enugu, South Eastern region of Nigeria. The hospital provides services mainly to patients from the five states that make up the South Eastern part of Nigeria. A total of 367 patients with schizophrenia from the out-patient department of the hospital were studied.

This was a hospital based descriptive cross-sectional study. Three hundred and sixty seven patients with International Classification of Diseases (ICD 10) diagnosis of schizophrenia confirmed with Present State Examination 10 (PSE-10) and not too ill to undergo the interview were included in the study. Patients were excluded if they declined to take part and if by self report or from medical records it was found that they had any other important disorder besides schizophrenia.

WHODAS II 12 Item Version was used to measure disability. It is a measure of global disability. The participants were asked to rate the level of difficulty they experienced (none 1, mild 2, moderate 3, severe 4, extreme 5), taking into consideration the ease in which they performed a given activity. Simple sum scoring method was used to calculate total disability. The internal consistency and test-retest reliability of the overall WHODAS 2.0 is high. WHODAS II has been used previously in Nigeria^{16,17}.

PANSS is a 30-item questionnaire that is used to assess patients' current mental state. The PANSS includes 30 items on 3 subscales: 7 items covering positive symptoms, 7 covering negative symptoms and 16 covering general psychopathology. Each item is scored on a seven-point item-specific Likert scale ranging from 1 to 7. Total Scores for the three scales were arrived at by summation of ratings across the component items. In addition, a composite scale was scored by subtracting negative from positive scores yielding a bipolar index (positive and negative), which was essentially a difference in score reflecting the degree of predominance of one syndrome in relation to the other¹⁸. Those who had equal scores in both scales were regarded as neither positive nor negative. PANSS has excellent internal consistency and inter-rater reliability. PANSS has been used previously in Nigeria¹⁹.

Patients who met the ICD 10 diagnosis of schizophrenia, made by a consultant psychiatrist or a senior trainee Psychiatrist (Resident Doctor) were selected. This diagnosis was confirmed using the schizophrenia schedule of PSE-10. Thereafter the socio-demographic questionnaire was administered to elicit information about age, gender, marital status, educational attainment employment status and age at onset of illness. For those who accepted ever smoking cigarettes, cigar or pipe in their life, PSE-10 smoking schedule was administered. The PSE-10 definition of "ever smoked" was adopted as the operational identification of "life time smoker", whereas "current smoking" referred to "having smoked in the past four weeks", irrespective of frequency or number of cigarettes²⁰. Those who smoked 1-10 cigarettes per day were classified as light smokers while those who smoked more than 10 cigarettes everyday were classified as heavy smokers^{21,22}. Early onset schizophrenia was classified as schizophrenia with onset before 18 years while late onset was above 18 years²³.

We measured and quantified the severity of psychotic symptoms of schizophrenia using Positive and Negative Syndrome Scale (PANSS) in all the participants. The total PANSS Score was recorded. Finally World Health Organization Disability Assessment Schedule II 12 item version (WHODAS II) was administered to measure disability in the previous month in all the participants. The

participants' WHODAS scores were dichotomized (yes/no) such that participants' with a total score of 12 were regarded as having no disability while scores above 12 indicated presence of disability²⁴. Daily doses of neuroleptics were converted into chlorpromazine equivalents (CPZ-eqs) for ease of statistical analysis.

Data was cleaned manually and analyzed using Computer software (Statistical Package for the Social Sciences Version 15). Statistical testing was conducted at the 5% significance level and 95% confidence interval. Gender, educational level, age of the participants, age of onset of schizophrenia, marital status, religion and employment status were presented as simple frequencies and percentages. Chi-square was used to test association between symptoms of schizophrenia and smoking status. PANSS score, number of cigarettes smoked per day, severity of smoking and dosage of anti-psychotic medications were entered into a multivariable regression model to adjust for confounders and identify predicting associations be-

tween these variables and disability scores. Associations between the mean number of cigarettes smoked per day and psychopathology; and between the mean number of cigarettes smoked per day and disability were tested using t-test. A p-value <0.05 was considered significant.

This study was approved by the Ethics Committee of the Federal Neuropsychiatric Hospital Enugu. Voluntary informed consent was sought and obtained from all the participants before recruitment into the study.

Results

Table 1 shows the characteristics of the participants. A total of 367 participants were included in the study. Most of the participants, 189 (51.5%) were females. Mean age of the participants was 34.1 ± 9.9 years. Mean age of onset of schizophrenia was 25.3 ± 6.5 years. The mean duration of schizophrenia illness was 8.76 ± 7.54 . Most of the participants, 241 (65.7%) had never been married. Most of the participants had late onset schizophrenia (85.3%). One hundred and seventy six (48.0%) of the participants had a predominance of negative symptoms.

Table 1. Socio-demographic and clinical characteristics of participants

Variables	N	Percent (%)
Gender		
Female	189	51.5
Male	178	48.5
Age (years)		
10-29	134	36.5
30-49	196	53.4
50-69	37	10.1
Mean ± S.D	34.1 ± 9.9	
Age of onset (years)		
Early onset schizophrenia	54	14.7
Late onset schizophrenia	313	85.3
Mean ± S.D	25.3 ± 6.5	
Duration of illness (years)		
Mean ± S.D	8.76 ± 7.54	
Marital status		
Married	87	23.7
Never married	241	65.7
Divorced	32	8.7
Widowed	7	1.9
Educational level		
No formal education	16	4.4
Primary education	59	16.1
Secondary education	203	55.3
Tertiary education	89	24.2
Religion		
Christian	364	99.2
Islam	3	0.8
Employment status		
Employed	164	44.7
Unemployed	203	55.3
Smoking status		
Ever smoked	95	25.9
Currently smokes	75	20.4
Severity of smoking		
Light smokers	2	2.7
Heavy smokers	73	97.3
Symptoms of schizophrenia		
Predominance of positive symptoms	113	30.7
Predominance of negative symptoms	176	48.0
Equal dominance	78	21.3
Total PANSS Score	45.01±11.89	
Disability		
Yes	313	85.3
No	54	14.7
Mean disability	22.03 ± 8.35	

Part of Table 1 was adapted from Table 1 of 'Aguocha C.M., Aguocha J.K., Monday Igwe, Unwakwe R.U., Onyeama G.M. Prevalence And Correlates Of Cigarette Smoking Among Patients With Schizophrenia In South East Nigeria. *Acta Psychiatrica Scandinavica* 11 SEP 2014 | DOI: 10.1111/aps.12334'

Table 2 Mean WHODAS and PANSS scores among the participants.					
Variable		Mean	Standard deviation	Test statistic	p-value
WHODAS Ever smoked	Yes	22.9	8.1	F= 1.52	p=0.22
	No	21.7	8.4		
Currently smokes	Yes	24.0	8.1	F= 5.39	p=0.02*
	No	21.5	8.3		
PANSS Ever smoked	Yes	44.2	9.5	F=0.6	p= 0.44
	No	45.3	12.6		
Currently smokes	Yes	44.8	10.0	F=0.04	p=0.85
	No	45.1	12.3		

F=One Way ANOVA

Table 2 shows that current smokers had a significantly higher mean WHODAS score of 24.0 ± 8.1 compared to 21.5 ± 8.3 for those that were not current smokers ($F= 5.39$, $p= 0.02$). The current smokers had a higher mean disability score (24.0 ± 8.1) compared to the lifetime smokers (22.9 ± 8.1). Among all the participants studied, the mean PANSS score was 45.01 ± 11.89 with range 30-94. There was no significant difference in the mean PANSS scores of those who had never smoked

and current and lifetime smokers. Multiple regression was used to predict disability from Total PANSS score, dosage of antipsychotics and number of cigarettes smoked per day. Total PANSS score significantly predicted disability $\beta=0.35$, $F(3, 71) = 4.16$, $p=0.00$, $R^2 = 0.19$). There was a weak positive linear relationship between mean WHODAS Score and total PANSS Score ($r=0.43$, $p= 0.0001$) and between dosage of anti-psychotics prescribed and number of cigarettes smoked daily ($r=0.27$, $p=0.009$) among the current smokers.

Table 3 Association between smoking, disability and clinical psychopathology

Variable	Frequency	Percent	Stat	p-value
Lifetime smoking				
	Yes (%)	No (%)		
Predominance of Negative symptoms	50 (52.6)	126 (46.3)	$X^2=5.72$	$p=0.06$
Predominance of Positive symptoms	33 (34.8)	80 (29.4)	d.f=2	
Equal dominance	12 (12.6)	66 (24.3)		
Current smoking				
Predominance of Negative symptoms	41 (54.7)	135 (46.2)	$X^2=4.88$	$p=0.09$
Predominance of Positive symptoms	25 (33.3)	88 (30.2)	d.f=2	
Equal dominance	9 (12.0)	69 (23.6)		
Mean No. of cigarettes smoked per day and disability				
Disability	N (%)	Mean No. of cigarettes smoked per day	Stat	p-value
Yes	71 (94.7)	3.90 ± 3.62	$t= -1.04$	$p=0.30$
No	4 (5.3)	2.00 ± 0.82		
Mean No. of cigarettes smoked per day and psychopathology				
	N (%)	Mean No. of cigarettes smoked per day	Stat	p-value
Predominance of Positive symptoms	25	3.56 ± 3.26	$t= -0.73$	$p=0.47$
Predominance of Negative symptoms	41	4.24 ± 4.23		

Table 3 showed greater rate of smoking among those with predominantly negative symptoms. There was no significant association between number of cigarettes smoked per day, disability scores ($t=-1.04$, $p=0.30$) and PANSS composite scores ($t=-0.73$, $p=0.47$).

Discussion

Research regarding the clinical characteristics of cigarette smokers with schizophrenia has produced mixed results, which may be attributed to methodological and sampling differences²⁵. Reduced rate of smoking in these patients compared to those in developed countries, differing antipsychotic medications, dosage of anti-psychotics and male to female ratio can account for this. A high rate of heavy smoking (97.3%) was found among the partic-

ipants in this study. It was higher than 52% previously reported²⁶. This difference can be attributed to variations in the cut off scores for heavy smoking²⁶. Countries, especially developed countries with higher rate of smoking may tend to use a higher cut off²⁰.

Most of the participants (48%) had a predominance of negative symptoms. This is higher than 25% and 15.8% reported in some other studies^{27,28}. This may be due to differences in sampling methods, help seeking behavior, duration of untreated psychosis, long schizophrenia illness and effect of medications leading to an increase in negative symptoms^{27,28}. Long duration of untreated psychosis found in developing countries, has been recorded among patients with predominantly negative symptoms²⁸. Current smoking was demonstrated to be significantly as-

sociated with disability. This is consistent with what has been found in some other studies^{29,30}. This has been attributed to smoking being a marker for a more severe schizophrenic illness^{25,31}.

There was no significant association between smoking status and psychopathology. This is consistent with what has been previously reported³². In fact, contrary to what was expected, smokers had lesser total clinical psychopathology scores compared to non-smokers. This may be due to smoking inducing relaxation and pleasurable feelings and reducing anxiety, anger and depression³³. These effects may have greater importance among patients with schizophrenia because their other sources of pleasure and satisfaction are likely diminished³³. This supports what has been reported previously that there is little evidence to support that tobacco use worsens the symptoms of schizophrenia^{14,34}.

Smoking status was not significantly associated with predominance of positive or negative symptoms. This agrees with reports of no statistically significant differences between schizophrenia smokers and non-smokers with regard to the severity of negative symptoms^{30,35,36}. Some other studies have reported that patients with more severe negative symptoms tend to smoke more to alleviate the symptoms of schizophrenia and that more severe negative symptoms were independently associated with current smoking^{37,38,39}. Reduced dopamine neurotransmission associated with chronic substance may be the cause of increased negative symptoms among these patients¹⁰. Clinical psychopathology was independently associated with disability among current smokers. This supports studies that have reported that though modest, increased psychopathology was associated with increased disability⁴⁰. It also agrees with reports of total PANSS and Brief Psychiatric Rating Scale (BPRS) scores having a significant positive correlation with disability^{13,41}.

Limitation

The study was a cross-sectional non-population representative study with small number of participants, it included only out-patients with schizophrenia, so its results cannot easily be generalized to the entire population. Secondly, the estimation of cigarette smoking habits was by self-report. A hundred percent reliability cannot be guaranteed. Assessing nicotine dependence with more specific meth-

ods, such as pack-year smoking history and Fagerstrom test for nicotine dependence is required in further studies.

Conclusion

Smoking in Nigerian schizophrenia patients is associated with significant disability and psychopathology. It calls for urgent measures to be implemented to discourage smoking among Nigerian patients with schizophrenia.

Conflict of interest

There is no conflict of interest.

References

1. The WHO World Health Report 2001: New Understanding, New Hope, 2001. Accessed 1st June 2016;
2. World Health Organization. Prevalence of tobacco smoking in Nigeria. Geneva: WHO 2001. Accessed 1st June 2016.
3. Marneros A, Diester A, and Rhode A. Psychopathological and social status of patients with affective, schizophrenic and schizoaffective disorders after long-term course. *Acta Psychiatrica Scand.* 1990; 82 : 352-358 PubMed .
4. Bowie CR, Depp C, McGrath JA, Wolyniec P, Mausbach BT, Thornquist MH, et al. Prediction of Real-World Functional Disability in Chronic Mental Disorders: A Comparison of Schizophrenia and Bipolar Disorder. *Am J Psychiatry.* 2010;167:1116-1124 PubMed .
5. Shihabuddeen I, Harpreet M, Pinto AP. Disability in Schizophrenia and Bipolar Mood disorder at a General Hospital Psychiatry Unit. *Delhi Psychiatry Journal* 2011; 14(2):258-261.
6. Williams JM. and Foulds J. Successful Tobacco Dependence Treatment in Schizophrenia. *Am J Psychiatry* 2007; 164:222-227 PubMed .
7. Jablensky A. Epidemiology of schizophrenia: The global burden of disease and disability, *European Archives of Psychiatry & Clinical Neuroscience.* 2000; 250(6): 274-285.
8. Wiersma D, Wanderling J, Dragomirecka E, Ganev K, Harrison G, An Der Heiden W, Nienhuis F, et al. Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres. *Psychol. Med.* 2000; 30: 1155–1167. PubMed
9. Wancata J, Freidl M, Friedrich F, Matschnig T, Unger A, Stockinger A, Dantendorfer K. Disability in schizophrenic disorders. *European Psychiatry.* 2009; 24: (S1) S209
10. Volkow N. Substance Use Disorders in Schizophre-

- nia—Clinical Implications of Comorbidity. *Schizophrenia Bulletin*. 2009; 35(3):469–472.
11. Wette R, Konig H, Leidl R. The Costs of Health Damage and Productivity Losses Attributable to cigarette Smoking in Germany. *European J. of Public Health* 2006; 10(1):31-38. PubMed
 12. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lönnqvist J. Incidence of Cancer Among Persons With Schizophrenia and Their Relatives. *Arch Gen Psychiatry* 2001; 58(6):573-578. doi:10.1001/archpsyc.58.6.573.
 13. Goff D, Henderson D, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side-effects. *American Journal of Psychiatry* 1992; 149:1189–1194.
 14. George TP, Vessicchio JC, Termine A, Sahady DM, Kosten TR. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. *Neuropsychopharmacology* 2002; 26:75–85.
 15. George TP. Neurobiological links between nicotine addiction and schizophrenia. *J Dual Diagn*. 2007; 3:27-42.
 16. Ogundele AT. Risk factors for disability among depressed elderly people living in a Nigerian community. Dissertation submitted to the West African college of Physicians 2009; 28-40.
 17. Bella TT and Omigbodun O. Social phobia in Nigerian university students: prevalence, correlates and co-morbidity. *Soc Psychiatry Psychiatr Epidemiol*. 2009; 44:458.
 18. Kay SR, Fiszbein A, Opler LA (1987). "The positive and negative syndrome scale (PANSS) for schizophrenia." *Schizophr Bull* 13 (2): 261–76.
 19. Adeosun I. Correlates of Caregiver Burden among Family Members of Patients with Schizophrenia in Lagos, Nigeria *Schizophr Res Treatment*. 2013; Article ID 353809, 7 pages doi: 10.1155/2013/353809.
 20. Aguocha CM, Aguocha JK, Igwe M, Uwakwe RU, Onyema GM. Prevalence and correlates of cigarette smoking among patients with schizophrenia in southeast Nigeria. *Acta Psychiatr Scand*. 2014; 1–7 DOI: 10.1111/acps.12334.
 21. Biener L, Albers AB. Young adults: Vulnerable new targets of tobacco marketing. *American Journal of Public Health*. 2004;94:326–330.
 22. Hajek P, West R, Wilson J. Regular smokers, lifetime very light smokers, and reduced smokers: comparison of psychosocial and smoking characteristics in women. *Health Psychol*. 1995; 14: 195–201. PubMed
 23. Clemmensen L, Vernal DL, Steinhausen HC (2012). "A systematic review of the long-term outcome of early onset schizophrenia". *BMC Psychiatry*. 12: 150. PMC 3521197 Freely accessible. PMID 22992395. doi:10.1186/1471-244X-12-150.
 24. Herran A, Santiago A, Sandoya M, Fernandez M, Diez-Manrique J, Vazquez-Barquero J. Determinants of smoking behaviour in outpatients with schizophrenia. *Schizophrenia Research*. 2000; 41:373–381.
 25. Yan-Min X, Hong-Hui C, Fu L, Fang D, Xiao-Bo L, Hai-Chen Y, Li-Guo Q, Jin-Hong G, and Tie-Bang L. Prevalence and Correlates of Cigarette Smoking among Chinese Schizophrenia Inpatients Receiving Antipsychotic Mono-Therapy. *PLoS One*. 2014; 9(2): e88478. doi: 10.1371/journal.pone.0088478.
 26. Woolhand J, Lasser K, Boydler S, Himmelstein D, McCormick D, Bor D. Smoking and mental illness. A population based prevalence study. *JAMA* 2000;284:2606–2610. PubMed
 27. Granö N, Lindsberg J, Karjalainen M, Grönroos P and Blomberg A. Duration of untreated psychosis is associated with more negative schizophrenia symptoms after acute treatment for first-episode psychosis. *Clinical Psychologist*. Volume 14, Issue 1; 2010; 10–13.
 28. Odinka PC, Ndukuba AC, Muomah RC, Oche M, Osika MU, Bakare MO, Agomoh AO and Uwakwe R. Positive and negative symptoms of schizophrenia as correlates of help-seeking behaviour and the duration of untreated psychosis in south-east Nigeria. *SAJP - November 2014 Vol. 20 No. 4*. <http://dx.doi.org/10.7196/sajp.536>
 29. McEvoy J, Allen P, Trina B. Substance abuse (including nicotine) in schizophrenic patients. *Current Opinion in Psychiatry*. 2003; 16 (2) 199-205;
 30. Hou Y, Xiang Y, Yan F, Ungvari G, Dickerson F, Chiu H, Lai K, Lee E, Li W, Li W, Zhu Y and Dixon L. Cigarette smoking in community-dwelling patients with schizophrenia in China. *Journal of Psychiatric Research*. 2011; 45 (12):1551-6.
 31. De Leon, J. Smoking and vulnerability for schizophrenia. *Schizophrenia Bulletin*. 1996; 22, 405–409.
 32. Barnes M, Lawford BR, Burton SC, Heslop KR, Noble EP, Hausdorf K, Young RM . Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? *Aust N Z J Psychiatry*. 2006 Jun-Jul;40(6-7):575-80.
 33. Edward R and Lyon MSA Review of the Effects of Nicotine on Schizophrenia and Antipsychotic Medications. *Psychiatr Serv* 1999; 50:1346-1350.

34. Ziedonis DM, and George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. *Schizophrenia Bulletin*. 1997; 23:247-254.
35. Zhang XY, Chen DC, Xiu MH, Haile CN, He SC, Luo X, Zuo L, Rosenheck R, Kosten TA, Kosten TR. Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study. *Psychol Med*. 2013 Aug; 43(8):1651-60
36. Tang YL, George TP, Mao PX, Cai ZJ, Chen Q (2007) Cigarette smoking in Chinese male in patients with schizophrenia: a cross-sectional analysis. *J Psychiatr Res* 41: 43–48.
37. Ziedonis D, Kosten T, Glazer W, Frances R. Nicotine dependence and schizophrenia. *Hospital and Community Psychiatry*. 1994; 45: 204 -206
38. Hall R, Duhamel M, McClanahan R, Miles G, Nason C, Rosen S, et al. Level of functioning, severity of illness, and smoking status among chronic psychiatric patients. *J Nerv Men Dis*. 1995; 183:468–471.
39. Beratis S., Katrivanou A. and Gourzis P. Factors affecting smoking in schizophrenia. *Comprehensive Psychiatry* 2001; 45, 393-402.
40. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity and symptoms. *Am J Psychiatry* 2006; 163:418–25. PubMed
41. Manabendra M, Uttam M, Amitava D, Shantanu D, Nirmal K. Disability in Persons with Schizophrenia: Its Correlation with Psychopathology and Socio-Demographic Profile. *Indian Medical Gazette*. 2013; 335-344.